Gubra (GUBRA) Resumen de Acciones
Gubra A/S es una empresa biotecnológica dedicada a la investigación preclínica por contrato y al descubrimiento de fármacos a base de péptidos para enfermedades metabólicas y fibróticas en Europa, Norteamérica y el resto del mundo. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 3/6 |
| Crecimiento futuro | 1/6 |
| Rendimiento pasado | 4/6 |
| Salud financiera | 6/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
GUBRA Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Gubra A/S
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | DKK 330.20 |
| Máximo en las últimas 52 semanas | DKK 571.00 |
| Mínimo de 52 semanas | DKK 293.00 |
| Beta | 0.25 |
| Cambio en 1 mes | 1.91% |
| Variación en 3 meses | -16.57% |
| Cambio de 1 año | -28.37% |
| Variación en 3 años | 252.40% |
| Variación en 5 años | n/a |
| Variación desde la OPV | 200.18% |
Noticias y actualizaciones recientes
GUBRA: Obesity Pipeline Progress And Phase 2 Milestones Will Drive Long Term Upside
Analysts have trimmed their price target for Gubra from DKK 469.50 to DKK 451.50, citing slightly softer revenue growth expectations and a modestly lower projected profit margin. This is partly offset by a small reduction in the discount rate and a marginally lower future P/E assumption.Analysts' Revenue Estimates For Gubra A/S (CPH:GUBRA) Are Surging Higher
Gubra A/S ( CPH:GUBRA ) shareholders will have a reason to smile today, with the analysts making substantial upgrades...GUBRA: Obesity Trial Pipeline Will Drive Long Term Upside
Analysts have kept their DKK 469.50 price target on Gubra unchanged, citing only minor tweaks to inputs such as discount rate, revenue growth, profit margin and forward P/E assumptions, rather than any shift in their overall view. What's in the News Gubra has called its annual general meeting for March 26, 2026, with the board proposing to renew and extend its authorization to issue warrants, including an increase of 120,277 warrants and an extension of the authorization period to March 26, 2031 (Key Developments).Recent updates
GUBRA: Obesity Pipeline Progress And Phase 2 Milestones Will Drive Long Term Upside
Analysts have trimmed their price target for Gubra from DKK 469.50 to DKK 451.50, citing slightly softer revenue growth expectations and a modestly lower projected profit margin. This is partly offset by a small reduction in the discount rate and a marginally lower future P/E assumption.Analysts' Revenue Estimates For Gubra A/S (CPH:GUBRA) Are Surging Higher
Gubra A/S ( CPH:GUBRA ) shareholders will have a reason to smile today, with the analysts making substantial upgrades...GUBRA: Obesity Trial Pipeline Will Drive Long Term Upside
Analysts have kept their DKK 469.50 price target on Gubra unchanged, citing only minor tweaks to inputs such as discount rate, revenue growth, profit margin and forward P/E assumptions, rather than any shift in their overall view. What's in the News Gubra has called its annual general meeting for March 26, 2026, with the board proposing to renew and extend its authorization to issue warrants, including an increase of 120,277 warrants and an extension of the authorization period to March 26, 2031 (Key Developments).GUBRA: Obesity Study And Ventures Unit Will Drive Long Term Upside
Analysts have kept their DKK 469.5 price target on Gubra unchanged, citing only marginal adjustments to assumptions such as the discount rate and forward P/E as the basis for this maintained view. What's in the News Gubra submitted a clinical trial application in Germany for GUB-UCN2, a first in human Phase 1/2a study designed to assess safety, tolerability, pharmacokinetics and preliminary efficacy, including muscle volume and muscle function endpoints, in about 188 participants across multiple indications and patient groups (Key Developments).GUBRA: Obesity Trial And Ventures Expansion Will Drive Future Upside Potential
Analysts have kept their DKK price target for Gubra unchanged at DKK469.50, citing essentially stable assumptions on discount rate, revenue trajectory, profit margin and forward P/E as reasons to maintain their prior valuation view. What's in the News Clinical trial application submitted in Germany for GUB-UCN2, a first in human Phase 1/2a study targeting high quality weight loss, with about 188 participants across multiple indications and patient groups, including combination use with incretin based therapy for obesity (Product Related Announcement).GUBRA: Future Obesity Trial And Ventures Platform Will Drive Upside Potential
Analysts have kept their DKK 469.5 price target on Gubra unchanged, citing model adjustments that reflect a slightly higher discount rate, softer revenue expectations, a lower projected profit margin and a higher future P/E multiple. What's in the News Gubra submitted a clinical trial application in Germany for GUB-UCN2, a first in human Phase 1/2a study aimed at high quality weight loss, with a design that looks at safety, tolerability, pharmacokinetics, preliminary efficacy, muscle volume and muscle function in about 188 participants, including both healthy volunteers and people living with obesity, as a standalone therapy and in combination with incretin based treatment.GUBRA: Future Pipeline Milestones And Royalties Will Drive Upside Potential
Analysts have reduced their price target for Gubra from DKK 502.50 to DKK 469.50, reflecting updated views on discount rates, revenue contraction, profit margins and a significantly lower future P/E multiple. What's in the News Gubra plans an Analyst and Investor Day event, giving the market a closer look at its business model, pipeline and long term priorities (Key Developments).AbbVie Agreement And Clinical Trials Will Unlock New Avenues
The significant downward revision in Gubra’s consensus price target reflects lowered expectations for future growth and earnings, as evidenced by reduced forecasts for both revenue growth and the future P/E multiple, resulting in a new fair value estimate of DKK540. What's in the News Extraordinary cash dividend of DKK 1 billion (DKK 61.2 per share) approved at EGM.Gubra A/S' (CPH:GUBRA) 35% Jump Shows Its Popularity With Investors
Gubra A/S ( CPH:GUBRA ) shares have had a really impressive month, gaining 35% after a shaky period beforehand...AbbVie Agreement And Clinical Trials Will Unlock New Avenues
Strategic partnerships and collaborations with top pharma companies ensure sustainable revenue streams and growth opportunities for Gubra.We're Not Worried About Gubra's (CPH:GUBRA) Cash Burn
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Gubra A/S' (CPH:GUBRA) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Gubra A/S ( CPH:GUBRA ) shareholders that were waiting for something to happen have been dealt a blow with a 26% share...We're Not Very Worried About Gubra's (CPH:GUBRA) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Gubra A/S' (CPH:GUBRA) Shares Climb 25% But Its Business Is Yet to Catch Up
Gubra A/S ( CPH:GUBRA ) shareholders would be excited to see that the share price has had a great month, posting a 25...Subdued Growth No Barrier To Gubra A/S (CPH:GUBRA) With Shares Advancing 60%
Despite an already strong run, Gubra A/S ( CPH:GUBRA ) shares have been powering on, with a gain of 60% in the last...Rentabilidad de los accionistas
| GUBRA | DK Life Sciences | Mercado DK | |
|---|---|---|---|
| 7D | -6.2% | -1.1% | -2.9% |
| 1Y | -28.4% | -6.6% | -20.0% |
Rentabilidad vs. Industria: Los resultados de GUBRA fueron inferiores a los de la industria Danish Life Sciences, que obtuvo un rendimiento del -6.6% el año pasado.
Rentabilidad vs. Mercado: GUBRA obtuvo unos resultados inferiores a los del mercado Danish, que fueron del -20% el año pasado.
Volatilidad de los precios
| GUBRA volatility | |
|---|---|
| GUBRA Average Weekly Movement | 6.0% |
| Life Sciences Industry Average Movement | 7.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DK Market | 9.0% |
| 10% least volatile stocks in DK Market | 2.8% |
Precio estable de las acciones: GUBRA no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado Danish.
Volatilidad a lo largo del tiempo: La volatilidad semanal de GUBRA (6%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2008 | 300 | Markus Rohrwild | www.gubra.dk |
Gubra A/S, empresa biotecnológica, se dedica a la investigación preclínica por contrato y al descubrimiento de fármacos a base de péptidos para enfermedades metabólicas y fibróticas en Europa, Norteamérica e internacionalmente. La empresa opera a través de tres segmentos: Investigación preclínica por contrato (CRO), Descubrimiento y asociaciones, y Gubra Green. Ofrece servicios preclínicos de investigación y desarrollo por contrato en el ámbito de las enfermedades metabólicas y fibróticas para la industria farmacéutica y biotecnológica, así como servicios de farmacología in vivo, ensayos de biomarcadores, bioinformática, secuenciación de última generación, farmacocinética e histología 2D y 3D con patología de inteligencia artificial.
Resumen de fundamentos de Gubra A/S
| Estadísticas fundamentales de GUBRA | |
|---|---|
| Capitalización bursátil | DKK 5.39b |
| Beneficios(TTM) | DKK 1.69b |
| Ingresos (TTM) | DKK 2.64b |
¿Está GUBRA sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de GUBRA | |
|---|---|
| Ingresos | DKK 2.64b |
| Coste de los ingresos | DKK 80.08m |
| Beneficio bruto | DKK 2.56b |
| Otros gastos | DKK 866.16m |
| Beneficios | DKK 1.69b |
Últimos beneficios comunicados
Dec 31, 2025
Próxima fecha de beneficios
Aug 20, 2026
| Beneficios por acción (BPA) | 103.51 |
| Margen bruto | 96.96% |
| Margen de beneficio neto | 64.11% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado GUBRA a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/06/03 20:40 |
| Precio de las acciones al final del día | 2026/06/03 00:00 |
| Beneficios | 2025/12/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Gubra A/S está cubierta por 3 analistas. 2 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Rune Dahl | DNB Carnegie |
| Jesper Ilsøe | DNB Carnegie |
| Rajan Sharma | Goldman Sachs |